Detecting Cancer While It Is Still Small Impacts Survival
the ONA take:
Detecting breast cancers when they are small still impacts survival despite the various effective therapies, a study published in The BMJ has shown.
Because breast cancer survival rates have significantly improved over the last few decades, mostly due to earlier diagnosis and more effective treatment options, traditional prognostic factors such as tumor size and number of positive lymph nodes are thought to no longer affect survival.
Therefore, researchers in the Netherlands sought to compare survival by tumor size and nodal status in patients with breast cancer during 1995 to 2005 with 2006 to 2012.
Researchers analyzed the overall survival data of 173,797 female patients with breast cancer. They found that tumors diagnosed during the 2006 to 2012 period were smaller, less likely to be lymph node positive, and more often low grade.
Patients with diagnoses during that time were also more likely to have undergone breast-conserving therapy, and the use of hormonal therapy, chemotherapy, and drug therapy were increased.
Results showed that relative survival rates and overall survival rates were higher for the 2006 to 2012 cohort for all tumor and nodal stages, particularly in women ages 75 years and older. The study demonstrated that both tumor stage and nodal status had a significant impact on overall survival in patients from both groups.
“Through public health screening and innovations in treatment, we are making steady progress against breast cancer,” the authors write. “A challenge ahead is to help other societies build models of screening and treatment that foster the access and success of the Dutch experience.”
Detecting breast cancers when they are small still impacts survival despite the various effective therapies.
Sign Up for Free e-newsletters
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- Handling Chemotherapy Premedications
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|